Advances in GLP-1 treatment: focus on oral semaglutide
Abstract Background There is currently a large arsenal of antidiabetic drugs available to treat type 2 diabetes (T2D). However, this is a serious chronic disease that affects millions of adults worldwide and is responsible for severe complications, comorbidities, and low quality of life when uncontr...
Main Authors: | Freddy G. Eliaschewitz, Luis Henrique Canani |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-09-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13098-021-00713-9 |
Similar Items
-
A Peptide in a Pill – Oral Semaglutide in the Management of Type 2 Diabetes
by: Selvarajan R, et al.
Published: (2023-06-01) -
Glycemic treatment effect of oral semaglutide plus other antidiabetic medications: An Indian experience
by: Manoj Chawla, et al.
Published: (2022-01-01) -
Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
by: Baptist Gallwitz, et al.
Published: (2021-06-01) -
Oral semaglutide: the innovation in type 2 diabetes management
by: M. V. Shestakova, et al.
Published: (2021-09-01) -
Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)